The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus
causing acute respiratory tract infection in humans. The virus has the characteristics of rapid …

The recent emergence of B. 1.1. 529, the Omicron variant,, has raised concerns of escape
from protection by vaccines and therapeutic antibodies. A key test for potential …

The recent emergence of SARS-CoV-2 Omicron (B. 1.1. 529 lineage) variants possessing
numerous mutations has raised concerns of decreased effectiveness of current vaccines …

Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or
Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most …

Despite the development and deployment of antibody and vaccine countermeasures, rapidly-
spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike protein …

Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …

SARS-CoV-2 is the etiological agent responsible for the ongoing COVID-19 pandemic,
which continues to spread with devastating effects on global health and socioeconomics …

Background: The emergence of the Brazilian variant of concern, Gamma lineage (P. 1),
impacted the epidemiological profile of COVID-19 cases due to its higher transmissibility …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disclose the variants of
concern (VOC) including Alpha (B. 1.1. 7), Beta (B. 1.351), Gamma (P1), Delta (B. 1.617. 2) …